Endocryte Ipo Analysis

1826 Words8 Pages
ENDOCRYTE IPO ANALYSIS The company that I chose to conduct my IPO on is called Endocyte. Endocyte just went public in July 2011 and is currently being traded on the NASDAQ with a Global Market symbol of (ECYT). Here is a little background on Endocyte as a company as well as the industry they are in: Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company uses proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnostics. SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. Endocyte is also developing companion imaging diagnostics for each of the SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. This combination of an SMDC with its companion imaging diagnostic is designed to personalize the treatment of patients by delivering effective therapy, selectively to diseased cells, in the patients most likely to benefit. The lead SMDC, EC145, targets the folate receptor, which is frequently over-expressed in some of the most prevalent, and difficult to treat solid tumor indications, including ovarian, non-small cell lung, breast, colorectal, kidney, endometrial and other cancers. They identify the presence of the folate receptor in cancer patients by using EC20, a proprietary companion imaging diagnostic for EC145. Endocyte has chosen platinum-resistant ovarian cancer, or PROC, a highly treatment-resistant disease, as its lead indication for development

More about Endocryte Ipo Analysis

Open Document